Anebulo raises $15M via private placement, FDA supports development of IV selonabant for pediatric cannabis toxicity

Anebulo Pharmaceuticals, Inc.

Raised $15M gross from sale of 15.2M shares at $0.99/share; change of control as director Aron English now owns >50% of common stock.
FDA acknowledged unmet need for pediatric cannabis toxicity and proposed close collaboration to efficiently advance IV selonabant program.
Plans to begin Phase 1 SAD study of IV selonabant in healthy adults in 1H 2025.
Will modify Loan & Security Agreement with 22NW and JFL Capital: reduce max loan to ~$3M, remove securitization.

item 1.01 item 3.02 item 5.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.